

S 4303

Interchangeable Biologics Clarity Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 25, 2022

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introdu

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710) (May 25, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/4303>

Sponsor

Name: Sen. Kaine, Tim [D-VA]

Party: Democratic • **State:** VA • **Chamber:** Senate

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Collins, Susan M. [R-ME]	R · ME		May 25, 2022
Sen. Hassan, Margaret Wood [D-NH]	D · NH		Jun 16, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 25, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.

Summary (as of May 25, 2022)

Interchangeable Biologics Clarity Act

This bill provides a statutory definition for *first interchangeable biosimilar biological product* and makes other technical changes with respect to the provisions that establish the corresponding periods of market exclusivity.

Actions Timeline

- **May 25, 2022:** Introduced in Senate
- **May 25, 2022:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S2709-2710)